Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents

por van Tetering, Geert, Evers, Mitchell, Chan, Chilam, Stip, Marjolein, Leusen, Jeanette
Publicado 2020

Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains

por Stip, Marjolein C., Jansen, J. H. Marco, Nederend, Maaike, Tsioumpekou, Maria, Evers, Mitchell, Olofsen, Patricia A., Meyer-Wentrup, Friederike, Leusen, Jeanette H. W.
Publicado 2023

Effective, Long-Term, Neutrophil Depletion Using a Murinized Anti-Ly-6G 1A8 Antibody

por Olofsen, Patricia A., Stip, Marjolein C., Jansen, J. H. Marco, Chan, Chilam, Nederend, Maaike, Tieland, Ralph G., Tsioumpekou, Maria, Leusen, Jeanette H. W.
Publicado 2022

hMRP8-ATTAC Mice: A New Model for Conditional and Reversible Neutrophil Ablation

por Duits, Danique E. M., Salvagno, Camilla, Raeven, Elisabeth A. M., Vrijland, Kim, Stip, Marjolein C., Hau, Cheei-Sing, Kaldenbach, Daphne, de Visser, Karin E.
Publicado 2022

Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma

por Evers, Mitchell, Stip, Marjolein, Keller, Kaylee, Willemen, Hanneke, Nederend, Maaike, Jansen, Marco, Chan, Chilam, Budding, Kevin, Nierkens, Stefan, Valerius, Thomas, Meyer-Wentrup, Friederike, Eijkelkamp, Niels, Leusen, Jeanette
Publicado 2021

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models

por Stip, Marjolein C, Evers, Mitchell, Nederend, Maaike, Chan, Chilam, Reiding, Karli R, Damen, Mirjam J, Heck, Albert J R, Koustoulidou, Sofia, Ramakers, Ruud, Krijger, Gerard C, de Roos, Remmert, Souteyrand, Edouard, Cornel, Annelisa M, Dierselhuis, Miranda P, Jansen, Marco, de Boer, Mark, Valerius, Thomas, van Tetering, Geert, Leusen, Jeanette H W, Meyer-Wentrup, Friederike
Publicado 2023